Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (Nasdaq: MNKD) announced its participation in two upcoming conferences, featuring CEO Michael Castagna, PharmD as a presenter. The events include the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, and the 2021 Cantor Global Virtual Healthcare Conference on September 27, 2021. Interested individuals can access live webcasts and replays on the company’s website for 14 days post-event. MannKind is known for developing inhaled therapeutic products, including Afrezza, an FDA-approved inhaled insulin available in the U.S. and Brazil.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 23rd Annual Global Investment Conference, available on demand from September 13, 2021. Interested parties can access the webcast through the Company’s Events & Presentations section on their website, where a replay will be available for 14 days. MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, including Afrezza®, the only inhaled ultra rapid-acting mealtime insulin in the U.S.
United Therapeutics Corporation (Nasdaq: UTHR) showcased the BREEZE study results for Tyvaso DPI™ at the European Respiratory Society Congress 2021. This next-generation inhalation solution for pulmonary arterial hypertension (PAH) demonstrated significant safety and tolerability, with 96% completion rate in a three-week trial. Key findings included an 11.5-meter increase in six-minute walk distance and enhanced patient satisfaction with the device. The FDA is expected to review Tyvaso DPI's NDA in October 2021, which could enhance therapeutic accessibility for PAH patients.
MannKind Corporation (MNKD) reported Q2 2021 revenues of $23.3 million, a 54% increase year-over-year, driven by Afrezza net revenue of $10.0 million. The company reported a net loss of $35.5 million, or $0.14 per share, compared to a net loss of $10.3 million in Q2 2020. Gross profit from Afrezza surged 68% to $5.6 million, enhancing gross margin to 56% (or 76% on a non-GAAP basis). Cash equivalents amounted to $201.4 million as of June 30, 2021, bolstered by $230 million in convertible notes issued earlier this year.
NRx Pharmaceuticals has partnered with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil) for respiratory conditions. Utilizing MannKind's Technosphere® platform, the collaboration aims to create an inhalable delivery system that enhances patient convenience. ZYESAMI™ has shown promising results in clinical trials for COVID-19 patients. NRx has received Fast Track Designation from the FDA and is conducting phase 3 trials for both intravenous and inhaled formulations, funded by the NIH and BARDA.
MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) to explore a dry powder formulation of ZYESAMI (aviptadil), aimed at treating respiratory failure due to COVID-19. Currently, ZYESAMI's intravenous formulation is in clinical trials with FDA Fast Track Designation. MannKind's CEO emphasized the potential of their Technosphere technology for delivering treatments effectively. The research is set to occur at MannKind's Danbury facility, which has significant production capabilities.
MannKind Corporation (Nasdaq:MNKD) will announce its Q2 2021 financial results on August 11, 2021, at 5 PM ET. The conference call will feature insights from CEO Michael Castagna and CFO Steven B. Binder. Investors can access the call and the subsequent replay on MannKind's website. MannKind focuses on inhaled therapeutic products, notably the FDA-approved Afrezza, the only inhaled ultra-rapid-acting insulin available in the U.S. and Brazil. The company was founded in 1991 and is based in Westlake Village, California.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 12:30 PM (ET). This event is exclusive to BTIG clients. MannKind focuses on developing and marketing inhaled therapies for patients with endocrine and orphan lung diseases. Its leading product is Afrezza®, the only inhaled ultra-rapid-acting mealtime insulin available in the U.S. for prescription.
MannKind Corporation (Nasdaq: MNKD) is partnering with U.S. professional racing driver Conor Daly, who has Type 1 diabetes, to engage local youth during the Music City Grand Prix week. Scheduled for August 4, 2021, Daly will share his diabetes journey and racing tips while racing go-karts with participants. Known for his resilience, Daly was diagnosed at 14 yet has competed successfully in over 70 Indy car races. This initiative aims to inspire youth and raise awareness of living with diabetes, emphasizing that it should not limit one's aspirations.
MannKind Corporation (Nasdaq: MNKD) announced a positive policy change by the Centers for Medicare and Medicaid Services (CMS) effective July 18, 2021. This change to the Local Coverage Determination (LCD) L33822 allows Medicare patients with diabetes to use both Afrezza® and Continuous Glucose Monitors (CGMs) simultaneously. Previously, patients had to choose between the two, which resulted in Medicare denials. MannKind's CEO emphasized the importance of patient convenience, while experts anticipate broader access for Afrezza users, enhancing diabetes management options.
